Top Markets
Coin of the day
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
株式のランク #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
株価
$0.1
最終同期: 2024-06-18
時価総額
$1.31M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Pascal Biosciences Inc. (PSCBF)

カテゴリー

Pascal Biosciences Inc.(PSCBF)の利益
Feb 2024 時点の利益 TTM: $-247.59K
Pascal Biosciences Inc. の最新の財務報告によると、同社の現在の利益は $-247.59K です。2022 年には $-359.87K の利益を上げ、これは 2021 年の利益 $-853.00K と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Pascal Biosciences Inc. の利益の推移(2019 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-247.59K -15.84%
2023 $-294.20K -18.25%
2022 $-359.87K -57.81%
2021 $-853.00K -9.78%
2020 $-945.48K -63.20%
2019 $-2.57M 0.00%
同業他社の利益
企業 利益 利益の差
$5.27B -2,130,610.56%
US
$1.95B -787,959.61%
NL
- -
CH
- -
KR
$3.01B -1,214,096.90%
BE